Study supports the dosing regimen that will be pursued in further clinical programsNo serious adverse events or QT prolongation identifiedPlanning underway to discuss results and the ongoing clinical program with the FDA DANBURY, Conn.…
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine…
Complete response received by United Therapeutics cites an open inspection issue at a third-party analytical testing center; no other deficiencies citedNo issues identified regarding operations performed at MannKind’s manufacturing…
WESTLAKE VILLAGE, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung…